Correlation of Quantitative EEG in Acute Ischemic Stroke With 30-Day NIHSS Score
-
- Simon P. Finnigan
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Stephen E. Rose
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Michael Walsh
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Mark Griffin
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Andrew L. Janke
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Katie L. McMahon
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Rowan Gillies
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Mark W. Strudwick
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Catharine M. Pettigrew
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- James Semple
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- John Brown
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Peter Brown
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
-
- Jonathan B. Chalk
- From the Centre for Magnetic Resonance (S.F., S.E.R., M.W., M.G., A.L.J., K.L.M., R.G., M.W.S., J.B.C.), the Department of Speech Pathology and Audiology (C.M.P.), and the Department of Medicine (J.B.C.), University of Queensland, Brisbane, Australia; the Translational Medicine and Technology Group (J.S., J.B.), GlaxoSmithKline, Cambridge, United Kingdom; the Academic Department of Psychiatry (J.S.), University of Cambridge, Cambridge, United Kingdom; and the Sobell Department of Motor Neuroscience...
書誌事項
- タイトル別名
-
- Comparison With Diffusion and Perfusion MRI
説明
<jats:p> <jats:bold> <jats:italic>Background and Purpose—</jats:italic> </jats:bold> Magnetic resonance imaging (MRI) methods such as diffusion- (DWI) and perfusion-weighted (PWI) imaging have been widely studied as surrogate markers to monitor stroke evolution and predict clinical outcome. The utility of quantitative electroencephalography (qEEG) as such a marker in acute stroke has not been intensively studied. The aim of the present study was to correlate ischemic cortical stroke patients’ clinical outcomes with acute qEEG, DWI, and PWI data. </jats:p> <jats:p> <jats:bold> <jats:italic>Materials and Methods—</jats:italic> </jats:bold> DWI and PWI data were acquired from 11 patients within 7 and 16 hours after onset of symptoms. Sixty-four channel EEG data were obtained within 2 hours after the initial MRI scan and 1 hour before the second MRI scan. The acute delta change index (aDCI), a measure of the rate of change of average scalp delta power, was compared with the National Institutes of Health Stroke Scale scores (NIHSSS) at 30 days, as were MRI lesion volumes. </jats:p> <jats:p> <jats:bold> <jats:italic>Results—</jats:italic> </jats:bold> The aDCI was significantly correlated with the 30-day NIHSSS, as was the initial mean transit time (MTT) abnormality volume (ρ=0.80, <jats:italic>P</jats:italic> <0.01 and ρ=0.79, <jats:italic>P</jats:italic> <0.01, respectively). Modest correlations were obtained between the 15-hour DWI lesion volume and both the aDCI and 30-day NIHSSS (ρ=0.62, <jats:italic>P</jats:italic> <0.05 and ρ=0.73, <jats:italic>P</jats:italic> <0.05, respectively). </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> In this small sample the significant correlation between 30-day NIHSSS and acute qEEG data (aDCI) was equivalent to that between the former and MTT abnormality volume. Both were greater than the modest correlation between acute DWI lesion volume and 30-day NIHSSS. These preliminary results indicate that acute qEEG data might be used to monitor and predict stroke evolution. </jats:p>
収録刊行物
-
- Stroke
-
Stroke 35 (4), 899-903, 2004-04
Ovid Technologies (Wolters Kluwer Health)
